Avidity Biosciences Inc
NASDAQ: RNAM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sarah Boyce
- Employees
- 511
- Headquarters
- San Diego, United States
- IPO year
- 2020
- Market cap
- $11.3B
- Website
- http://www.aviditybiosciences.com
Loading RNAM…
Loading profile data…Frequently asked questions about RNAM
What does Avidity Biosciences Inc (RNAM) do?
Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of...
Where does RNAM trade?
Avidity Biosciences Inc (RNAM) trades on the NASDAQ Global Market.
What sector is RNAM in?
Avidity Biosciences Inc (RNAM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Avidity Biosciences Inc?
Sarah Boyce is the chief executive officer of Avidity Biosciences Inc (RNAM).
Where is Avidity Biosciences Inc headquartered?
Avidity Biosciences Inc is headquartered in United States.
Does RNAM pay a dividend?
Avidity Biosciences Inc (RNAM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNAM go public?
Avidity Biosciences Inc (RNAM) completed its initial public offering in 2020.